Clinical trial NCT03029741: Bioavailability of AZD0284 and IV Microtracer Study
Official title: A Phase I Study To Assess The Absolute Bioavailability Of A Single Oral Dose Of AZD0284 And To Assess The Pharmacokinetics Of A Single Intravenous Microdose Of [14C]AZD0284 In Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Plaque Psoriasis Vulgaris
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2017-01-24
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. It occurs when skin cells are replaced more quickly than usual. The seriousness of psoriasis varies greatly from person to person. For some people it is a minor irritation, but for others it can have a major impact on their quality of life. .

The purpose of the study is to determine how much of AZD0284 is taken up by the body. The safety and tolerability of the drug will also be assessed. It is hoped that the study drug will improve the management of psoriasis.

Detailed description: The study is a Phase I, single centre, open-label, non-randomized, single dose study performed in 6 healthy male subjects aged 18 to 65 years, inclusive. The study will assess the absolute bioavailability of a single oral dose of AZD0284 and the pharmacokinetics (PK) of a single intravenous (IV) microdose of \[14C\]AZD0284 in healthy male and female subjects. Oral AZD0284 and \[14C\] AZD0284 intravenous solution are referred to as the investigational products in this study.

A screening visit to assess the eligibility of the healthy male and female subjects will occur within 28 days of the administration of the investigational product. Screening assessments will include medical history, inclusion/exclusion criteria, demographic data, weight and height, vein assessment, physical examination, blood samples for haematology, clinical chemistry and virology, blood test to confirm post-menopausal status (if female and of non-childbearing potential), blood test to confirm no history of tuberculosis, urine sample for urinalysis, urine test for pregnancy (if female and of childbearing potential) drug screen, alcohol breath test, carbon monoxide (CO) breath test, heart monitoring using ECG, vital signs (blood pressure, heart rate) Study related procedures will only be performed after signing of the Informed Consent Form.

The healthy male and female subjects will be admitted to the study centre the day before administration of the investigational product (Day -1). On Day 1, subjects will be dosed with a single oral dose of 4 to 120 mg AZD0284 oral suspension (Regimen A) followed by 20 μg \[14C\]AZD0284 solution for IV infusion (Regimen B) beginning 3 hours after the oral dose has been administered. The IV microdose will be infused over 15 minutes and the end of the infusion is expected to be around the predicted tmax of Regimen A.

The subjects will remain in the study centre until the 48 hour post dose PK blood sample is obtained. A follow up visit will occur 5 to 7 days after dosing and will include PK and routine safety assessments.

Eligibility criteria: Inclusion Criteria:

1. Signed and dated, written informed
2. Healthy males or non-pregnant, non-lactating healthy females.
3. Age 18 to 65 years of age.
4. Suitable veins for cannulation or repeated venepuncture.
5. Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling 1 of the following criteria:

   * Post-menopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the postmenopausal range.
   * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
6. Body mass index of 18.0 to 30.0 kg/m2, inclusive, or, if outside the range, considered not clinically significant by the investigator, and weigh at least 50 kg and no more than 100 kg, inclusive.
7. Must be willing and able to communicate and participate in the whole study.
8. Must agree to use an adequate method of contraception

Exclusion

1. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results of the volunteer's ability to participate in the study.
2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational medicinal product (IMP).
4. Subject who have increased risk of infection History and/or presence of tuberculosis (TB) positive result for IFN-y release assay (IGRA) (ie QuantiFERON TB-Gold). The test may be repeated if the initial test result is indeterminate.

   Is in a high-risk group for human immunodeficiency virus (HIV) infection within the last 6 months.

   Subjects with a disease history suggesting abnormal immune function in the judgement of the investigator. (This does not include mild allergy such as childhood asthma or eczema).
5. Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis, as judged by the investigator.
6. Any clinically significant abnormal findings in vital signs, as judged by the investigator.
7. Any clinically significant abnormal findings in 12-lead ECG, as judged by the investigator.
8. Any positive result at screening for serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or HIV results.

Primary outcomes:
measure: Determination of absolute bioavailability of AZD0284
timeFrame: PK blood samples: pre-dose, post oral dosing at hour, 0.5, 1, 2, 0, 0.5, 1, 2, 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5,3.75, 4, 5, 6, 7, 8, 9, 11, 12, 15, 24, 27, 36, 48 and 72.
measure: Cmax for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: Tmax for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: AUC(0-last) for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: AUC(0-inf) for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: AUC%extrap for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: lambda-z for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: T1/2 for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: CL (total clearance) for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: Vz for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: Vss for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: MRT (mean residence time) for [14C]AZD0284
timeFrame: PK blood samples:pre-dose, time relative to oral dosing at hour: 2.83, 2.92, 2.92, 3, 3.08, 3.17, 3.33, 3.5, 3.75, 4, 5, 6, 7, 8, 9, 11, 15, 27, 36, 48 and 72.
measure: Cmax for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
measure: Tmax for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
measure: Tlag for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
measure: AUC (0-last) for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
measure: AUC(0-inf) for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
measure: AUC%extrap for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
measure: lambda-z for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
measure: T1/2 for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
measure: CL/F for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 36, 48 and 72.
measure: Vz/F for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36 , 36, 48 and 72.
measure: MRT for AZD0284
timeFrame: PK blood samples: pre-dose, time relative to oral dosing at hour, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72.
Secondary outcomes:
measure: To collect further information about the safety and tolerability of AZD0284 by assessing physical examinations.
timeFrame: Targeted physical examination:screening, pre-dose, time relative to oral dosing at hour 72.
measure: To collect further information about the safety and tolerability of AZD0284 by assessing telemetry
timeFrame: Continuous ECG monitoring will commence approximately 10 minutes before dosing commences until 24 hours after the oral dose.
measure: To collect further information about the safety and tolerability of AZD0284 by assessing safety laboratory tests
timeFrame: Haematology and clinical chemistry:screening, pre-dose, time relative to oral dosing at hour 24 and 72, virology at screening.
measure: To collect further information about the safety and tolerability of AZD0284 by assessing vital signs
timeFrame: Blood pressure and pulse rate: screening, pre-dose, post oral dosing at hour 1, 2, 3, 4, 6, 8, 12, 24 and 72.
measure: To collect further information about the safety and tolerability of AZD0284 by assessing 12 Lead Electrocardiogram (ECG)
timeFrame: ECGs: screening, pre-dose, post oral dosing at hour, 1, 2, 3, 4, 6, 8, 12, 24 and follow up.
Other outcomes:
Locations:
city: Nottingham
country: United Kingdom
facility: Research Site
Study officials:
affiliation: Quotient Clinical Ltd, United Kingdom
name: Philip Evans, MBChB, MRCS
role: PRINCIPAL_INVESTIGATOR
References: